Hypertensive retinopathy in a rat model: modulation by an endothelin-receptor antagonist

被引：0
|
作者：
de Gooyer, TE
McDonald, L
McDonald, D
Lee, GR
Canning, P
Kelso, EJ
McDermott, BJ
Stitt, AW
机构：
[1] Queens Univ Belfast, Ophthalm Res Ctr, Belfast BT7 1NN, Antrim, North Ireland
[2] Queens Univ Belfast, Cardiovasc Res Ctr, Belfast BT7 1NN, Antrim, North Ireland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2004年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3256
引用
收藏
页码：U94 / U94
页数：1
相关论文
共 50 条
  • [1] Effects of an Endothelin Receptor Antagonist on a Model of Hypertensive Retinopathy
    McDonald, Louise
    Lee, Graham R.
    deGooyer, Tanyth E.
    McDonald, Denise
    Canning, Paul
    Kelso, Elizabeth J.
    McDermott, Barbara J.
    Stitt, Alan W.
    [J]. OPHTHALMIC RESEARCH, 2010, 43 (02) : 99 - 107
  • [2] Endothelin-Receptor Antagonist Treatment of Portopulmonary Hypertension
    Hinterhuber, Lukas
    Graziadei, Ivo W.
    Kaehler, Christian M.
    Jaschke, Werner
    Vogel, Wolfgang
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) : 1039 - 1042
  • [3] Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin
    Weber, C
    Banken, L
    Birnboeck, H
    Schulz, R
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (08): : 847 - 854
  • [4] Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: Safety and pharmacokinetics
    Carducci, MA
    Nelson, JB
    Bowling, MK
    Rogers, T
    Eisenberger, MA
    Sinibaldi, V
    Donehower, R
    Leahy, TL
    Carr, RA
    Isaacson, JD
    Janus, TJ
    Andre, A
    Hosmane, BS
    Padley, RJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (08) : 2171 - 2180
  • [5] Endothelin-receptor gene-expression in rat endotoxemia
    Michael Bucher
    Kai Taeger
    [J]. Intensive Care Medicine, 2002, 28 : 642 - 647
  • [6] Endothelin-receptor gene-expression in rat endotoxemia
    Bucher, M
    Taeger, K
    [J]. INTENSIVE CARE MEDICINE, 2002, 28 (05) : 642 - 647
  • [7] Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension
    Halank, M
    Miehlke, S
    Hoeffken, G
    Schmeisser, A
    Schulze, M
    Strasser, RH
    [J]. TRANSPLANTATION, 2004, 77 (11) : 1775 - 1776
  • [8] Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects
    Weber, C
    Schmitt, R
    Birnboeck, H
    Hopfgartner, G
    vanMarle, SP
    Peeters, PAM
    Jonkman, JHG
    Jones, CR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) : 124 - 137
  • [9] EFFECT OF AN ENDOTHELIN-RECEPTOR ANTAGONIST ON ISCHEMIC ACUTE-RENAL-FAILURE
    CHAN, L
    CHITTINANDANA, A
    SHAPIRO, JI
    SHANLEY, PF
    SCHRIER, RW
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01): : F135 - F138
  • [10] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
12345